In The Star's annual year in review, the county's biggest business stories included housing proposals and the aftermath of a ...

It took 27 years, but Cytokinetics secured its first U.S. drug approval. On Friday, the Food and Drug Administration cleared ...

An announcement from Anbio Biotechnology Class A ( ($NNNN) ) is now available. On December 30, 2025, Anbio Biotechnology reported unaudited ...

On December 19, 2025, the National Security Commission on Emerging Biotechnology (NSCEB) announced the publication of a paper entitled “The Future of U.S.-China Biotechnology Competition.” The paper ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.

Discover how intellectual property rights protect exclusive pharmaceutical use and brand names in biotechnology, influencing innovation and market dynamics.